3
H index
0
i10 index
16
Citations
Martina Garau : Citation Profile
Office of Health Economics | RESEARCH PRODUCTION: 1 Articles 5 Papers 1 Books RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
49 years (1970 - 2019). Relations with other researchers
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Martina Garau. | Is cited by:
| Cites to:
|
Main data
Where Martina Garau has published?
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Briefing / Office of Health Economics | 4 |
Recent works citing Martina Garau (2024 and 2023)
| Year | Title of citing document |
|---|---|
| 2023 | Barriers and facilitators to implementing priority setting and resource allocation tools in hospital decisions: A systematic review. (2023). Cutler, Henry ; Gu, Yuanyuan ; Seil, Elizabeth ; Bilgrami, Anam ; Jeet, Varinder ; Ahumada-Canale, Antonio. In: Social Science & Medicine. RePEc:eee:socmed:v:322:y:2023:i:c:s0277953623001478. Full description at Econpapers || Download paper |
Works by Martina Garau:
| Year | Title | Type | Cited |
|---|---|---|---|
| 2009 | Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries In: Briefing. [Full Text][Citation analysis] | paper | 6 |
| 1970 | Estimating Pharmaceutical Companies Value to the Nation: Case Study of the British Pharma Group In: Briefing. [Citation analysis] | paper | 0 |
| 2018 | Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward In: Briefing. [Full Text][Citation analysis] | paper | 4 |
| 2019 | How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy In: Briefing. [Citation analysis] | paper | 3 |
| 2007 | European Medicines Pricing and Reimbursement: Now and the Future In: Monograph. [Full Text][Citation analysis] | book | 0 |
| 2011 | Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Paper. [Full Text][Citation analysis] | paper | 2 |
| 2018 | Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 1 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated November, 3 2024. Contact: CitEc Team